DOI: 10.1038/s41467-022-30649-1; PMCID: PMC9142524
Neutralization capacity of antibodies against Omicron after a prior SARS-CoV-2 infection in children and adolescents is not well studied. Therefore, we evaluated virus-neutralizing capacity against SARS-CoV-2 Alpha, Beta, Gamma, Delta and Omicron variants by age-stratified analyses (5 years of age. As expected, convalescent pediatric COVID-19 and MIS-C cohorts demonstrate higher neutralization titers than hospitalized acute COVID-19 patients. Overall, children and adolescents show some loss of cross-neutralization against all variants, with the most pronounced loss against Omicron. In contrast to SARS-CoV-2 infection, children vaccinated twice demonstrated higher titers against Alpha, Beta, Gamma, Delta and Omicron. These findings can influence transmission, re-infection and the clinical disease outcome from emerging SARS-CoV-2 variants and supports the need for vaccination in children.
Adolescent; Antibodies, Viral; COVID-19; Child; Child, Preschool; Humans; Membrane Glycoproteins; Neutralization Tests; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Systemic Inflammatory Response Syndrome; Viral Envelope Proteins
Viral Antibodies; COVID-19; Membrane Glycoproteins; Neutralization Tests; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Systemic Inflammatory Response Syndrome; Viral Envelope Proteins
Tang J, Novak T, Hecker J, et al. Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C. Nat Commun. 2022;13(1):2979. Published 2022 May 27. doi:10.1038/s41467-022-30649-1